Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours

Exclusion Criteria

• •Clinically significant non-malignant disease.
• •Active CNS metastases.
• •Subjects with uncontrolled diabetes.
• •History of clinically significant adverse drug reaction to heparin or other anti-coagulant agents
• •History of immune-mediated thrombocytopaenia or other platelet abnormalities or other hereditary or acquired coagulopathies.
• •Concomitant use of aspirin (\> 150 mg/day), NSAIDs (except COX-2 selective inhibitors), vitamin K antagonists (other than low-dose prophylactic use), heparin within two weeks prior to randomisation, or other anti-platelet drugs.
• •History of severe allergic, anaphylactic or other significant adverse reaction to radiographic contrast media
• •Known seropositivity to the human immunodeficiency virus (HIV)
• •Women who are pregnant or breast-feeding.
• •Women of child-bearing potential and male subjects who are partners of women of childbearing potential who are unable or unwilling to practice a highly effective means of contraception.
• •Active substance abuse
• •Subjects who have received an investigational agent within 28 days prior to Cycle 1 Day 1.